|
|||||
|
|
Patient-reported outcomes in RELAY,a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer |
|
| Authors: | Kiyotaka Yoh Shinji Atagi Martin Reck Edward B. Garon Santiago Ponce Aix Denis Moro-Sibilot |
| Affiliation: | 1. Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan kyoh@east.ncc.go.jp;3. Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan;4. Lungen Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany;5. David Geffen School of Medicine, University of California Los Angeles/TRIO-US Network, Los Angeles, CA, USA;6. Hospital Universitario, CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain;7. Grenoble University Hospital, Grenoble, France |
| Abstract: | Abstract ObjectiveIn the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated metastatic NSCLC (median PFS 19.4 versus 12.4?months; HR = 0.59, 95% CI = 0.46–0.76; p? |
| Keywords: | NSCLC ramucirumab erlotinib patient-reported outcomes EGFR mutation |